You are here: Industry Insights > Systemic Lupus Erythematosus

News List

Advances in the Research of Targeting B Cells for the Treatment of Systemic Lupus Erythematosus Xiaonisha
July 25, 2025
Systemic Lupus Erythematosus (SLE) is a chronic, systemic autoimmune disease. The direct cause of SLE pathogenesis lies in the immune imbalance resulting from excessive B-cell activation.
Research Progress in the Treatment of Systemic Lupus Erythematosus with Belimumab Xiaonisha
July 25, 2025
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with an unclear pathogenesis that can affect multiple organs throughout the body, primarily including the kidneys, joints, nervous system, and hematological system.
UCB and Biogen's lupus drug falls short at Phase 2b pharmafile
October 25, 2018
The partnership of UCB and Biogen announced disappointing news, confirming that its experimental therapy dapirolizumab pegol (DZP) failed to meet its primary endpoint in the treatment...
STELARA Shows Positive Results In Treatment of Systemic Lupus Erythematosus americanpharmaceuticacreview
November 07, 2017
Based on the results of the Phase 2 study results, Janssen plans to advance STELARA into a Phase 3 SLE development program in 2018.
GSK’s Benlysta receives Japanese MHLW approval for systemic lupus erythematosus pharmaceufical-technology
September 30, 2017
Indicated for patients who are inadequate responders to existing therapies, Benlysta is approved for use as an add-on therapy in autoantibody-positive SLE patients.